Omnitrope 30 IU Cartridge

Manufacturer: Sandoz

Pharmaceutical name: Somatropin

Pack: 1 cartridge (30IU (10mg/1.5ml))

Omnitrope is a man-made version of human growth hormone (HGH). HGH is a protein that naturally exists in the body and promotes the growth of bones and cartilage. Omnitrope is a recombinant protein, meaning it is created in a lab and has a structure nearly identical to that of natural HGH. It is an FDA-approved, user-friendly, and cost-effective treatment option for children who have a growth hormone deficiency. Omnitrope is available in packages of 5, either as 1.5ml/5mg (15iu) or 1.5ml/10mg (30iu) cartridges.

 

In pediatrics, Omnitrope is recommended for children experiencing growth failure due to growth hormone deficiency (GHD) or Prader-Willi syndrome (diagnosed through genetic testing). It is also used for children with SGA growth failure who are born small for gestational age and do not show catch-up growth by age 2, as well as for those with idiopathic short stature (with no identifiable cause) and girls with Turner Syndrome (who possess only one X chromosome). In adults, Omnitrope helps treat growth hormone deficiency that occurs in childhood or adulthood.

 

Omnitrope is not suitable for children who have acute critical illnesses, respiratory failure, cancer or active malignancies, active proliferative or non-proliferative diabetic retinopathy, known allergies to somatropin, closed epiphyseal plates, severe obesity, respiratory issues related to Prader-Willi Syndrome, or those recovering from trauma or post-surgery.

 

Before prescribing Omnitrope, doctors should monitor for the following: Signs of upper airway obstruction and sleep apnea in children with Prader-Willi Syndrome; any emerging symptoms necessitate discontinuation of treatment; Neoplasm: patients with existing tumors should be observed for progression or recurrence; childhood cancer survivors treated with somatropin have a higher risk of a secondary neoplasm, particularly meningiomas in those previously treated with radiation to the head; Blood glucose levels should be routinely monitored; diabetic patients might need adjustments to their anti-hyperglycaemic medications since impaired glucose tolerance and diabetes mellitus can be unmasked; Intracranial Hypertension could develop, which may be mitigated by reducing the dosage or halting treatment; Fluid retention, common